Addition of Trilaciclib May Mitigate Myelosuppression in Patients With Small Cell Lung Cancer
Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Read More